Monopar Therapeutics reports third quarter net loss of $3.4 million
Monopar Therapeutics Inc. reported a net loss of $3.4 million for Q3 2025, compared to $1.3 million in Q3 2024. The company holds $143.7 million in cash and investments. Recent developments include FDA clearance for MNPR-101-Lu, a Phase 1 trial, and preparations for a New Drug Application for ALXN1840. They also repurchased 550,229 shares for $35 million, following a public offering with net proceeds of $91.9 million.
Monopar Therapeutics Inc. reported a net loss of $3.4 million, or $0.48 per share, for the third quarter of 2025, compared to a net loss of $1.3 million, or $0.37 per share, for the same period in 2024. As of September 30, 2025, the company held $143.7 million in cash, cash equivalents, and investments. Recent business developments include FDA clearance of an IND application for MNPR-101-Lu, a Phase 1 trial for advanced or metastatic solid tumors, and preparations to submit a New Drug Application for ALXN1840 for Wilson disease in early 2026. The company also completed a share repurchase of 550,229 shares from Tactic Pharma for $35 million, following a public offering, resulting in net proceeds of approximately $91.9 million before expenses. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574781-en) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
